The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
The investigational Cytotoxicity Targeting Chimera targets the CCR2 receptor, highly expressed on malignant monocytes and bone marrow blasts to selectively eliminate disease-driving cells.
The analysis reviewed clinical data and samples from patients with MPN diagnosed at the authors’ center from 2018 to 2025 to characterize the prevalence and impact of JAK2G127D mutations. Next-generation sequencing was used to detect genetic mutations in samples, and cell models were used to evaluate the functional impact of co-occurring mutations. Out of 249 samples positive for JAK2V617F mutations, 15 carried a concurrent JAK2G127D mutation. Notably, JAK2G127D mutations only co-occured with JAK2V617F mutations.
Andrew Kuykendall, MD, an associate member from Moffitt Cancer Center, discusses updated data from the phase 2 RALLY-MF trial. The trial evaluated DISC-0974 in patients with myelofibrosis and anemia. DISC-0974 is a first-in-class monoclonal antibody designed to block hemojuvelin.
The analysis included 418 patients diagnosed with MF between January 2018 and January 2026 at 21 European centers. At time of diagnosis, 232 patients (55%) had proliferative MF and 186 (45%) had cytopenic MF, including 115 with moderate anemia, 41 with severe anemia, and 30 with leukopenia, thrombocytopenia, or combined cytopenias.
Andy Zeng, MD, PhD, of Princess Margaret Cancer Centre in Toronto, Canada, and colleagues presented the findings at the 2026 EHA Congress. The researchers sought to assess non-genetic factors to explain the heterogeneity of the clinical presentation and outcomes associated with MF. They assessed peripheral blood from 358 patients in a discovery cohort and 168 in a validation cohort.
Results from the MONUMENTAL-3 study showed that the combination of talquetamab and daratumumab with or without pomalidomide (Tal-DP/Tal-D) significantly improved survival compared with daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
